Lee HF, Chen SW, Liu JR, et al. - In this nationwide retrospective cohort study, researchers used the Taiwan National Health Insurance Research Database to analyze a longitudinal and national cohort comprising patients with type-2 diabetes mellitus (T2DM) and concomitant peripheral artery disease (PAD) in order to assess the risk of cardiovascular and limb events, as well as mortality related to the use of sodium glucose co-transporter 2 inhibitors (SGLT2i) vs dipeptidyl peptidase-4 inhibitors (DPP4i) in this patient population. Covariates across study groups were balanced by applying 1:1 propensity score matching. Findings revealed that lower risks of congestive heart failure and adverse lower limb events were observed in relation to treatment with SGLT2i vs DPP4i in patients with T2DM and PAD in real-world practice.